Search Results
Found 2 results
510(k) Data Aggregation
(197 days)
The models 438-07 and 435-07 pacing leads are intended for use with implantable cardiac pulse generators for long-term pacing of the heart. The indications for ventricular pacing include, but are not limited to: Sick sinus syndrome, sinus bradycardia, complete heart block, symptomatic second-degree heart block, and certain conditions of asymptomatic second-degree block. In the presence of normal A-V conduction the indications for atrial pacing include, but are not limited to: Sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias. Active-fixation leads are specifically indicated for use in cases where passivefixation leads provide unsatisfactory positional stability in either the atrium or the ventricle, or in cases where the atrial appendage has been sacrificed due to open-heart surgery or is abnormal because of congenital or acquired heart disease. In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual chamber pacing system to restore A-V synchrony.
The Intermedics Cardifix™ EZ Models 438-07 (bipolar) and 435-07 (unipolar) endocardial pacing leads are designed for use with implantable cardiac pulse generators configured for atrial or ventricular applications for long term cardiac pacing. The nominal length for the model 438-07 lead is 58 cm and is available in lengths from 40 to 110 cm. The nominal length for the model 435-07 lead is also 58 cm and is available in lengths from 40 to 110 cm. The lead connectors are designed to meet VS-1 specifications (an intra-industry agreement standardizing lead-to-pulse generator connection dimensions) for lead connectors. The models 438-07 and 435-07 pacing leads are packaged with the model 367-01 vein lifter and the following stylets: model 365-11 (straight stylet, limber), model 365-12 (straight stylet, firm), model 365-89 ("J" stylet, limber), and model 365-90 ("J" stylet, firm). The model 435-07 is also packaged with the following adapters: model 366-29 (Step up adapter, VS-1 unipolar lead to 5 mm unipolar pacer) and model 366-30 (Step up adapter. VS-1 unipolar lead to 6 mm unipolar pacer). The minimum introducer size recommended for the model 438-07 is 10 French. The minimum introducer size recommended for the model 435-07 is 7.5 French. The models 438-07 and 435-07 pacing leads are identical to the Intermedics models 438-05 (K922972, K954719) and 435-05 (K922972, K954719) respectively, except for the use of iridium-oxide (IROX) coated titanium for the electrodes. The IROX-coated electrodes are identical to those used in models 430-07 (K902672, K954719) and 431-07 (K902672, K954719) except that the dimensions of the cathode tip have been slightly modified to accommodate the active fixation corkscrew.
This document is a 510(k) summary for pacing leads, which are medical devices, not AI/ML software. Therefore, many of the requested categories related to AI/ML software performance studies are not applicable.
Here's an analysis of the provided text in relation to your request, indicating where information is present and where it is not applicable or unavailable:
1. A table of acceptance criteria and the reported device performance
The document does not present a formal table of acceptance criteria with reported quantitative performance metrics in the way one would describe for an AI/ML model (e.g., sensitivity, specificity, AUC thresholds). Instead, safety and effectiveness are established through:
- Design and Material Equivalence: The new models (438-07 and 435-07) are stated to be identical to predicate devices (438-05, 435-05, 430-07, 431-07) except for a minor modification to the cathode tip (IROX coating and slight dimension change to accommodate the corkscrew). This implies the acceptance criterion is equivalence to previously cleared devices.
- Biocompatibility Testing: The materials were evaluated in in vitro and in vivo tests (Hemolysis, MEM Elution Cytology, Ames Mutagenicity, USP Class V, Intramuscular Implantation, Maximization Sensitization, USP Pyrogen Test). The reported performance is that the materials "were not found to present any toxic liability under physiological conditions."
- Qualification Testing: "Complete qualification testing was performed on the predicate leads." For the new leads, specific testing was done on the modified tip to corkscrew joint "to verify the strength of this joint." The reported performance is "All of the test samples successfully completed the qualification testing."
- Clinical Experience of Predicate Devices: The "extremely low incidence of clinical complications" of the predicate devices (438-05, 435-05, 430-07, and 431-07) is cited as evidence of effective performance, and based on similarity, the new devices are "expected to perform with comparable efficacy."
Acceptance Criteria (Implied) | Reported Device Performance |
---|---|
Design and Materials: Equivalence to predicate devices | New models are identical to predicate devices except for minor cathode tip modification (IROX coating and dimensions for corkscrew). |
Biocompatibility: No toxic liability under physiological conditions | Materials "were not found to present any toxic liability under physiological conditions" based on various tests (in vitro/in vivo). |
Qualification Testing: Successful completion of tests (especially for modified joint) | All test samples for the tip to corkscrew joint "successfully completed the qualification testing." Predicate leads also underwent full qualification testing. |
Clinical Performance: Comparable efficacy to predicate devices | Predicate devices showed "extremely low incidence of clinical complications," and new devices are "expected to perform with comparable efficacy" due to similarity. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Test set sample size: Not explicitly stated. For biocompatibility, it refers to "test systems" and "test data." For qualification testing, it mentions "All of the test samples." No specific numbers or human patient count are provided for these tests.
- Data provenance: Not specified. The biocompatibility and qualification tests are laboratory/bench tests, not clinical studies with human data tied to specific locations or retrospective/prospective designations. The "clinical experience" cited is from commercially available predicate devices, implying real-world data but without details on its origin or nature (e.g., registries, individual reports).
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not applicable. This pertains to establishing ground truth for AI/ML models based on expert review. The studies described are engineering qualification tests and biocompatibility tests, not studies requiring expert review for ground truth in the context of diagnostic accuracy.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not applicable. This is relevant for studies where multiple readers or experts assess cases. The studies here are focused on device engineering and material properties.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not applicable. This is a medical device approval, not an AI/ML software. No MRMC study was performed, and there is no AI component.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not applicable. This is a medical device approval, not an AI/ML software. No algorithm is being evaluated.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- Ground truth for Biocompatibility: Laboratory test results based on established international standards (e.g., ISO for hemolysis, USP for pyrogen).
- Ground truth for Qualification Testing: Engineering specifications and successful completion of designed tests (e.g., strength of a joint).
- Ground truth for "Clinical Experience": Implied real-world performance data (low incidence of complications) from existing, commercially available predicate devices. This aligns somewhat with "outcomes data," but is presented as a general summation rather than a specific study.
8. The sample size for the training set
- Not applicable. There is no AI/ML model, and thus no training set.
9. How the ground truth for the training set was established
- Not applicable. There is no AI/ML model, and thus no training set or ground truth establishment for it.
In summary: The provided document is a 510(k) submission for conventional medical devices (pacing leads), relying on equivalence to predicate devices and results from engineering and biocompatibility tests. It does not involve AI/ML technology, and therefore, most of your questions related to AI/ML study design and performance metrics are not applicable to this specific document.
Ask a specific question about this device
(151 days)
Pacing leads and accessories are intended for use with implantable cardiac pulse generators for long-term pacing of the heart. The indications for ventricular . pacing include, but are not limited to: Sick sinus syndrome, sinus bradycardia, complete heart block, and certain conditions of asymptomatic second-degree block.
In the presence of normal A-V conduction the indications for atrial pacing include, but are not limited to: Sinus arrest, sick sinus syndrome, sinus bradycardia and conditions requiring increased cardiac efficiency, enhanced cardiac output or the overdrive of certain cardiac arrhythmias.
In the absence of normal A-V conduction, an atrial lead may be used with a ventricular lead in a dual-chamber pacing system to restore A-V synchrony.
Active fixation leads are specifically indicated for use in cases where passivefixation leads provide unsatisfactory positional stability in either the atrium or the ventricle, or in cases where the atrial appendage has been sacrificed due to open-heart surgery or is abnormal because of congenital or acquired heart disease.
Suture-on epicardial leads (model 439-04) and screw-on (sutureless) myocardial leads (model 439-07), placed on the outside of the heart, are indicated for use when cardiac pacing is indicated and a suture-on lead is preferred, or when an endocardial lead cannot achieve satisfactory results. Such leads are particularly well suited to patients whose age or heart condition requires that the potential for lead dislodgment be minimized (i.e. patients who have not reached full physical maturity) and patients who may require cardiac pacing following openchest surgery.
The Intermedics Models 431-04, 431-07, 433-02, 433-03, 435-02, 435-05, 435-07, 435-08, 437-02, and 437-07 endocardial pacing leads, model 439-04 epicardial pacing lead, model 439-07 myocardial pacing lead, implantable accessory models 365-07, 365-09, 365-14, 365-17, 365-19, 365-22, 365-33, 365-34, 365-44, 365-49, 366-13, 366-15, 366-27, 366-28, 366-29, and 366-30, and non-implantable accessory models 365-62, 365-77, 365-29, 366-02, 366-17, and 367-01, are designed for use with implantable cardiac generators for long term cardiac pacing.
The provided text is a 510(k) Summary for a change in the manufacturing process of Intermedics Pacing Leads and Accessories, specifically the elimination of Chlorofluorocarbons (CFCs). It is not a study proving device performance against acceptance criteria in the typical sense of a diagnostic medical device with performance metrics like sensitivity, specificity, etc.
Instead, this document describes how the CFC-free manufactured devices are substantially equivalent to previously approved devices. The "acceptance criteria" here are demonstrating that the change in manufacturing process does not negatively impact the device's safety and effectiveness, meaning the performance remains comparable to the predicate devices.
Here's a breakdown based on your request, interpreting "acceptance criteria" in this context as demonstrating equivalence:
1. A table of acceptance criteria and the reported device performance
Acceptance Criteria (Demonstrating Equivalence to Predicate Device) | Reported Device Performance (with CFC-free process) |
---|---|
Biocompatibility: Materials are not toxic under physiological conditions. | Biocompatibility: Tissue/fluid contacting materials (silicone, 80A polyurethane, 55D polyurethane) cleaned with IPA/heptane (CFC-free process) were re-tested for hemolysis and cytotoxicity and found to continue to be biocompatible. All materials from original devices were also evaluated and found biocompatible. |
Performance Equivalence: Device performance remains equivalent to commercially available leads. | Performance Equivalence: Based on qualification testing of representative models (431-07 and 435-08), performance is expected to be equivalent to Freon-TMS manufactured leads. Clinical experience of predicate devices shows low complications and effective performance. The CFC-free devices are expected to perform with comparable efficacy due to similar design and materials. |
Design and Materials: No changes to critical design characteristics or materials. | Design and Materials: With the exception of the manufacturing solution, the CFC-free leads/accessories are identically configured to the commercially available models. Detailed characteristics (electrode material, lead body material, fixation, connector) remain the same. |
Labeling: No changes to product labeling. | Labeling: There are no changes to the product labeling. |
Sterilization: Sterilization procedures remain effective. | Sterilization: Procedures utilize ethylene oxide (EO) sterilizers set for specific parameters derived from AAMI guidelines. Bioburden testing is performed. |
Manufacturing Controls: Consistent quality control in manufacturing. | Manufacturing Controls: Environmental controls are used, monitored, and bioburden testing is performed. Vendor approval and inspection process is in place. |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Test Set (Qualification Testing): Models 431-07 and 435-08 were selected for qualification testing. The document does not specify the number of units tested for each model, only that these models were "selected as they consist of processes representative of the changes."
- Data Provenance: Not explicitly stated as country of origin. The document is a 510(k) submission to the FDA (United States), so testing would typically be compliant with US regulatory standards. It describes testing of manufactured devices which is prospective in the sense of testing the new manufacturing process. The "clinical experience" cited for predicate devices is retrospective.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
Not applicable, as this is not a diagnostic device or a study involving expert interpretation of medical images/data to establish ground truth. The "ground truth" here is the established safety and effectiveness of the previously approved predicate devices and the performance metrics from standard engineering and biocompatibility tests.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
Not applicable. This is not a study requiring human adjudication of medical findings.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This document is for pacemaker leads, not AI-assisted diagnostic tools involving human readers.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
Not applicable. This is not an algorithm or AI device. The "standalone" performance relates to the physical and biological performance of the device components themselves.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The "ground truth" in this context is established through:
- Predicate Device Performance: The known long-term safety and effectiveness of the Intermedics pacing leads manufactured with Freon-TMS, which has been demonstrated through extensive clinical use.
- Biocompatibility Standards: Established in-vitro and in-vivo test systems (e.g., Hemolysis Test, MEM Elution Cytology, Ames Mutagenicity, USP Class V, Intramuscular Implantation, Maximization Sensitization, USP Pyrogen Test).
- Engineering Qualification Testing: Performance measured against engineering specifications for the device (though specific metrics are not detailed in this summary).
8. The sample size for the training set
Not applicable. This is not an AI/machine learning device requiring a training set.
9. How the ground truth for the training set was established
Not applicable.
Ask a specific question about this device
Page 1 of 1